C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Has $1.06 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 28.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,309 shares of the company's stock after selling 2,901 shares during the quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors' holdings in Johnson & Johnson were worth $1,057,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of JNJ. Powers Advisory Group LLC boosted its stake in Johnson & Johnson by 0.6% during the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock valued at $1,538,000 after purchasing an additional 61 shares during the period. Knuff & Co LLC grew its position in Johnson & Johnson by 0.7% in the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock worth $1,534,000 after purchasing an additional 64 shares during the last quarter. Vertex Planning Partners LLC grew its position in Johnson & Johnson by 1.3% in the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company's stock worth $844,000 after purchasing an additional 65 shares during the last quarter. Freedom Day Solutions LLC grew its position in Johnson & Johnson by 1.1% in the 3rd quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company's stock worth $1,016,000 after purchasing an additional 66 shares during the last quarter. Finally, Traphagen Investment Advisors LLC grew its position in Johnson & Johnson by 0.6% in the 3rd quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company's stock worth $1,699,000 after purchasing an additional 67 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Ratings Changes

Several research analysts have commented on the stock. Stifel Nicolaus decreased their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Wells Fargo & Company decreased their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Citigroup reduced their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Guggenheim upped their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.67.

Johnson & Johnson Trading Up 1.9 %

Shares of NYSE:JNJ traded up $2.94 during mid-day trading on Wednesday, hitting $157.93. The stock had a trading volume of 7,830,622 shares, compared to its average volume of 9,018,342. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market cap of $380.23 billion, a PE ratio of 23.75, a P/E/G ratio of 2.50 and a beta of 0.52. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company's 50 day moving average is $148.12 and its 200-day moving average is $155.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.29 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.14%. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark A. Weinberger acquired 1,000 shares of the company's stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.